Outlook Therapeutics Inc (OTLK)
7.78
+0.45
(+6.14%)
USD |
NASDAQ |
May 17, 16:00
7.78
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Total Return Level: 7.78 for May 17, 2024
Total Return Level Chart
Historical Total Return Level Data
Date | Value |
---|---|
May 17, 2024 | 7.78 |
May 16, 2024 | 7.33 |
May 15, 2024 | 7.43 |
May 14, 2024 | 7.40 |
May 13, 2024 | 7.54 |
May 10, 2024 | 7.58 |
May 09, 2024 | 7.73 |
May 08, 2024 | 8.00 |
May 07, 2024 | 8.21 |
May 06, 2024 | 8.50 |
May 03, 2024 | 8.60 |
May 02, 2024 | 8.50 |
May 01, 2024 | 8.50 |
April 30, 2024 | 8.92 |
April 29, 2024 | 9.10 |
April 26, 2024 | 8.43 |
April 25, 2024 | 8.19 |
April 24, 2024 | 8.20 |
April 23, 2024 | 8.20 |
April 22, 2024 | 8.09 |
April 19, 2024 | 8.17 |
April 18, 2024 | 8.29 |
April 17, 2024 | 8.61 |
April 16, 2024 | 8.75 |
April 15, 2024 | 8.62 |
Date | Value |
---|---|
April 12, 2024 | 8.70 |
April 11, 2024 | 9.04 |
April 10, 2024 | 8.99 |
April 09, 2024 | 9.26 |
April 08, 2024 | 9.35 |
April 05, 2024 | 9.26 |
April 04, 2024 | 9.52 |
April 03, 2024 | 9.12 |
April 02, 2024 | 9.70 |
April 01, 2024 | 10.26 |
March 28, 2024 | 11.94 |
March 27, 2024 | 9.37 |
March 26, 2024 | 8.68 |
March 25, 2024 | 8.51 |
March 22, 2024 | 8.63 |
March 21, 2024 | 7.04 |
March 20, 2024 | 6.78 |
March 19, 2024 | 7.405 |
March 18, 2024 | 7.785 |
March 15, 2024 | 8.24 |
March 14, 2024 | 5.73 |
March 13, 2024 | 6.462 |
March 12, 2024 | 6.992 |
March 11, 2024 | 7.818 |
March 08, 2024 | 7.904 |
Total Return Level Definition
The total return level allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions. Total return level is seen as the most accurate calculation that produces returns consistent with most other sources.
Total Return Level Range, Past 5 Years
4.072
Minimum
Sep 08 2023
66.20
Maximum
Feb 08 2021
26.36
Average
24.40
Median
Oct 23 2019
Total Return Level Benchmarks
Cutera Inc | 2.22 |
Actinium Pharmaceuticals Inc | 9.80 |
GT Biopharma Inc | 3.12 |
Karyopharm Therapeutics Inc | 1.15 |
Marinus Pharmaceuticals Inc | 1.33 |